Results 261 to 270 of about 38,942 (318)

Continuous Ranibizumab via Port Delivery System vs Monthly Ranibizumab for Treatment of Diabetic Macular Edema: The Pagoda Randomized Clinical Trial.

JAMA Ophthalmol
Khanani AM, Campochiaro PA, Graff JM, Marcus DM, Miller D, Mittra RA, Regillo C, Sheth VS, Bobbala A, Gune S, Lin S, Quezada-Ruiz C, Malhotra V.   +12 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Approved biosimilar ranibizumab—a global update

Eye, 2022
Ashish Sharma, M. Kondo, C. Iwahashi, N. Parachuri, Nilesh Kumar, F. Bandello, A. Loewenstein, B. Kuppermann   +7 more
semanticscholar   +3 more sources

Ranibizumab for Neovascular Age-Related Macular Degeneration

New England Journal of Medicine, 2006
Philip J Rosenfeld, Jeffrey S Heier, David S Boyer   +2 more
exaly   +2 more sources

Ranibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration

New England Journal of Medicine, 2011
Maureen G Maguire, Gui-shuang Ying, Juan E Grunwald   +2 more
exaly   +2 more sources

Ranibizumab

Drugs, 2007
Ranibizumab is the antigen-binding fragment of a recombinant, humanised monoclonal antibody, which binds with high affinity to, and inhibits the activity of, all active forms of vascular endothelial growth factor A, an important mediator in the development of choroidal neovascularisation.
Antona J. Wagstaff, Gillian M. Keating, Stephanie K A Blick   +2 more
  +10 more sources

Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): an open-label randomised controlled trial

Lancet, The, 2019
Andreas Stahl, Domenico Lepore, Michael F Chiang   +2 more
exaly   +2 more sources

Ranibizumab and Bevacizumab for AMD

New England Journal of Medicine, 2011
n engl j med 365;23 nejm.org december 8, 2011 2237 developed during the study, only 44 had macrolide resistance (41 ...
Tien Yin Wong, Chui Ming Gemmy Cheung
openaire   +3 more sources